Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab

Rheumatol Int. 2018 Jul;38(7):1301-1306. doi: 10.1007/s00296-018-4054-9. Epub 2018 May 17.

Abstract

Behçet's disease is a chronic inflammatory condition of unknown origin characterized by multiple organ involvement. The most common symptoms of Behçet's disease are recurrent oral and/or genital ulcerations in combination with symptoms affecting eyes, skin, central and peripheral nervous system, blood vessels and gastrointestinal tract. We present a 43-year-old female patient with the history of recurrent episodes of genital and oral ulcerations, elevated acute phase reactants and skin lesions. The diagnosis of Behçet's disease has been delayed (for more than 10 years) and reached only after she developed neurological and ocular symptoms. Treatment with glucocorticoids and azathioprine was partially successful. High doses of glucocorticoids were needed to control the disease and cyclosporine A was nephrotoxic. Remission was reached after the introduction of infliximab (plus methotrexate) and glucocorticoids were stopped. In the recent years, infliximab has been accepted as a standard therapy for refractory cases of Behçet's disease (neurological, ocular or gastrointestinal). Our patient presented with refractory ocular and neurological symptoms and infliximab was effective for both manifestations. Long-term side-effects of glucocorticoids and other immunosuppressants can be avoided with TNF-α blockade. We emphasize the importance of a timely and accurate diagnosis and significance of excluding more common diseases in a work-up algorithm.

Keywords: Behçet’s disease; Glucocorticoids; Infliximab; Neurologic and ocular involvement.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Behcet Syndrome / drug therapy*
  • Female
  • HLA-B51 Antigen / analysis
  • Humans
  • Infliximab / therapeutic use*
  • Prednisone
  • Quality of Life
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • HLA-B51 Antigen
  • Infliximab
  • Prednisone